Stonepine Capital Management LLC Sells 223,097 Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST)

Stonepine Capital Management LLC lessened its position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 15.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,239,199 shares of the company’s stock after selling 223,097 shares during the period. Milestone Pharmaceuticals comprises 1.5% of Stonepine Capital Management LLC’s portfolio, making the stock its 14th largest holding. Stonepine Capital Management LLC owned about 2.33% of Milestone Pharmaceuticals worth $1,636,000 at the end of the most recent reporting period.

Separately, Lion Point Capital LP boosted its holdings in shares of Milestone Pharmaceuticals by 1.7% during the 2nd quarter. Lion Point Capital LP now owns 2,340,207 shares of the company’s stock valued at $3,089,000 after acquiring an additional 40,000 shares during the last quarter. 86.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Milestone Pharmaceuticals in a report on Thursday, August 22nd. Rodman & Renshaw initiated coverage on shares of Milestone Pharmaceuticals in a research note on Thursday, August 22nd. They issued a “buy” rating and a $9.00 price objective for the company.

Milestone Pharmaceuticals Stock Performance

NASDAQ:MIST opened at $1.52 on Tuesday. The stock’s 50 day simple moving average is $1.45 and its two-hundred day simple moving average is $1.54. Milestone Pharmaceuticals Inc. has a 1 year low of $1.12 and a 1 year high of $3.52. The company has a debt-to-equity ratio of 1.61, a current ratio of 19.13 and a quick ratio of 19.13. The company has a market cap of $80.96 million, a price-to-earnings ratio of -1.22 and a beta of 1.71.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. As a group, equities analysts anticipate that Milestone Pharmaceuticals Inc. will post -0.71 earnings per share for the current fiscal year.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.